Trial · NCT02607293
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of subjects with polycystic ovary | Baseline | |
| Primary | Serum Testosterone levels | Baseline | |
| Primary | Number of subjects with history of menstrual disorders | Baseline | |
| Primary | Number of subjects with hirsutism | Baseline | |
| Primary | Number of oocytes retrieved | Baseline up to 2-7 days until end of stimulation cycle (approximately 28 days) | |
| Secondary | Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH) | Baseline up to 1 month | |
| Secondary | Daily Dose of Recombinant Follicle Stimulating Hormone (r-FSH) | Baseline up to 1 month | |
| Secondary | Number of Metaphase II (M II) oocyte retrieved | Baseline up to 2-7 days until end of stimulation cycle (approximately 28 days) | |
| Secondary | Biochemical pregnancy rate | 4 to 6 Weeks after Embryo transfer (Up to 4 months) | Biochemical pregnancy was defined as a positive pregnancy test (serum beta-hCG test) of the post-treatment assessment period |
| Secondary | Clinical pregnancy rate | 4 to 6 Weeks after Embryo transfer (Up to 4 months) | Clinical pregnancy was defined as existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat. |
| Secondary | Implantation Rate | 4 to 6 Weeks after Embryo transfer (Up to 4 months) | Implantation rate was measured as the number of gestational sacs observed, divided by the number of embryos transferred multiplied by 100. |
| Secondary | Number of Subjects With Ovarian Hyper Stimulation Syndrome (OHSS) | Baseline up to 13 month | OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, haemoconcentration, and increased blood clotting. |
| Secondary | Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS) | Baseline up to 13 month | OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, haemoconcentration, and increased blood clotting. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02607293/registered